Why MS looks different in every patient — and what that means for treatment

Multiple sclerosis doesn't follow a single script — and neurologists are getting a clearer picture of why. Experts now describe MS progression as a feedback loop: immune cells enter the central nervous system, activate microglia, and the inflammatory process sustains itself from within. Critically, where lesions form matters enormously. Spinal cord lesions and atrophy sit at the "shallow end" of the brain's reserve pool, meaning they're more likely to cause noticeable disability — yet the field has historically focused on brain imaging while underweighting the cord.

Adding to the complexity, MS is deeply heterogeneous. One patient may lose repair signals, another may show heightened effector cell activity, and another may be driven primarily by B-cell dysfunction. Genetics, sex, race, ethnicity, and comorbidities layer on even more variability, making it hard to predict trajectory or treatment response.

Key Takeaways:

• Lesion location — especially spinal cord involvement — is a critical but underappreciated driver of disability
• Progression can't be halted by targeting lesions alone; the immune feedback loop within the CNS must also be addressed
• Patient heterogeneity supports a precision medicine approach to MS management

Why it matters: Understanding why MS varies so widely between patients is the first step toward tailoring treatments that actually match each person's disease biology — moving the field beyond one-size-fits-all therapy.